Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Obesity
100%
Type 2 Diabetes Prevention
100%
Catcher
100%
Tirzepatide
100%
Exendin-4 Analogue
100%
Glucagon-like
40%
Glycemic Control
40%
Clinical Trials
20%
Comorbidity
20%
Therapeutic Potential
20%
Adipose Tissue
20%
Therapeutic Agents
20%
Bariatric Surgery
20%
Insulin Secretion
20%
New Treatment Options
20%
Insulin
20%
Randomized Controlled Clinical Trial
20%
Cardioprotection
20%
Highly Effective
20%
Obesity Type
20%
Metabolic Therapy
20%
Control Tissue
20%
Weight Reduction
20%
Appetite Control
20%
Glucose-dependent Insulinotropic Polypeptide
20%
Incretin-based Therapy
20%
Physiological Action
20%
Surgery for Obesity
20%
Improved Function
20%
Obesity Treatment
20%
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
20%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Gut
100%
Incretin
100%
Tirzepatide
100%
Glucagon Like Peptide 1
40%
Gastric Inhibitory Polypeptide
40%
Adipose Tissue
20%
Bariatric Surgery
20%
Clinical Trial
20%
Insulin Release
20%
Glycemic
20%
Receptor
20%
Therapeutic Agent
20%
Glycemic Control
20%
Controlled Clinical Trial
20%
Heart Protection
20%
Burden of Obesity
20%
Comorbidity
20%
INIS
diabetes mellitus
100%
obesity
100%
glucose
40%
control
40%
clinical trials
40%
insulin
40%
peptides
40%
polypeptides
40%
glucagon
40%
data
20%
therapy
20%
increasing
20%
surgery
20%
receptors
20%
comparative evaluations
20%
weight
20%
secretion
20%
adipose tissue
20%
therapeutic agents
20%
food and drug administration
20%
Pharmacology, Toxicology and Pharmaceutical Science
Incretin
100%
Tirzepatide
100%
Non Insulin Dependent Diabetes Mellitus
100%
Glucagon-Like Peptide-1
40%
Clinical Trial
20%
Receptor Agonist
20%
Controlled Clinical Trial
20%
Gastric Inhibitory Polypeptide
20%
Gastric Inhibitory Polypeptide Receptor
20%
Comorbidity
20%